Loading…

A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors

The emergence and worldwide spreading of Plasmodium falciparum strains that shown to be resistant to traditional drugs is considered a very serious health problem, given the high mortality and morbidity rate of Malaria. In the search for new drugs against this parasite, Hb hydrolyzing enzymes, such...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis 2004-03, Vol.34 (4), p.833-840
Main Authors: Salas, Emir, Ramı́rez, Angel, Otero-Bilbao, Anabel, Vázquez, Rayner, Reyes, Osvaldo, Mendiola, Judith, Duarte, Carlos A, Otero-González, Anselmo, Gutiérrez, Omar A, Chávez, Marı́a A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergence and worldwide spreading of Plasmodium falciparum strains that shown to be resistant to traditional drugs is considered a very serious health problem, given the high mortality and morbidity rate of Malaria. In the search for new drugs against this parasite, Hb hydrolyzing enzymes, such as Plasmepsin II (Plm II), have been classified as very promising targets for therapeutic attacks. In this work, it is developed a cheap and high-throughput heterogeneous enzymatic assay for measuring Plasmepsin II activity in order to use it as a tool in the discovery of new inhibitors of this enzyme. In this assay, Plasmepsin II acts upon a solid-phase bound synthetic peptide (DU2) whose sequence comprises the cleavage site F 33-L 34 present in Hb α-chain. The peptide surface density is quantified by means of a classical ELISA-based procedure. In order to estimate the kinetic constants of the system and to quantify both, enzymatic and inhibitory activity, it was used a model for the kinetics of enzyme quasi-saturable systems previously developed by our group, that fitted very well to the experimental data. It was used Pepstatin as a model inhibitor of Plasmepsin II and the resulting dose–response relation agreed with the expected behavior for the Pepstatin–Plasmepsin II pair under the employed experimental conditions.
ISSN:0731-7085
1873-264X
1873-264X
DOI:10.1016/S0731-7085(03)00566-1